HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Doxorubicin, cyclophosphamide, CCNU, and vincristine with or without cisplatinum in non-small cell lung cancer.

Abstract
To evaluate the role of cisplatinum in the treatment of advanced non-small cell lung cancer, 48 patients received either a doxorubicin (adriamycin) 50 mg/m2 I.V., cyclophosphamide 300 mg/m2 I.V., lomustine (CCNU) 50 mg/m2 p.o., vincristine (oncovin) 1.2 mg/m2 I.V. (ACCO) combination or the same drugs plus cisplatinum 50 mg/m2 I.V. (PACCO) in a prospective sequential trial. No patient had received prior chemotherapy. Patients receiving the two regimens were comparable with regard to median age, performance status, histologic subtype, disease extent, and weight loss. Objective response frequency was only 5% in the initial 20 patients receiving ACCO treatment compared to a response frequency of 28% (7% complete) in the 28 patients receiving cisplatinum in the PACCO treatment arm (p less than 0.06). Patients achieving objective response lived significantly longer than nonresponders (9.1 months vs. 3.8 months, p less than 0.05). Although median survival was similar on the two regimens (6.1 months for ACCO vs. 7.6 months for PACCO), more than four times as many patients were alive after 1 year in the PACCO treatment group (24% vs. 5%). Predominant toxicity consisted of moderately severe nausea and vomiting (63% on PACCO vs. 34% on ACCO, p less than 0.05) and myelosuppression with WBC less than 3,000/mm3 occurring in the majority of patients on both regimens. These results suggest cisplatinum addition to a doxorubicin, cyclophosphamide, lomustine, and vincristine combination may be associated with increased 1-year survival in the non-small cell lung cancer patient population.
AuthorsR T Chlebowski, J S Chlebowski, J Herrold, B Richardson, I Ali, J B Block, E Oktay
JournalAmerican journal of clinical oncology (Am J Clin Oncol) Vol. 8 Issue 2 Pg. 157-61 (Apr 1985) ISSN: 0277-3732 [Print] United States
PMID3914840 (Publication Type: Clinical Trial, Journal Article)
Chemical References
  • Vincristine
  • Lomustine
  • Doxorubicin
  • Cyclophosphamide
  • Cisplatin
Topics
  • Actuarial Analysis
  • Antineoplastic Combined Chemotherapy Protocols (adverse effects, therapeutic use)
  • Body Weight (drug effects)
  • Carcinoma (drug therapy, mortality, pathology)
  • Cisplatin (administration & dosage)
  • Clinical Trials as Topic
  • Cyclophosphamide (administration & dosage)
  • Doxorubicin (administration & dosage)
  • Female
  • Hematologic Diseases (chemically induced)
  • Humans
  • Lomustine (administration & dosage)
  • Lung Neoplasms (drug therapy, mortality, pathology)
  • Male
  • Middle Aged
  • Nausea (chemically induced)
  • Vincristine (administration & dosage)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: